1346229-51-3

Basic information

• Product Name: tert-butyl 4-oxo-1-oxa-9-azaspiro[5.5]undecane-9-carboxylate
• Synonyms: tert-butyl 4-oxo-1-oxa-9-azaspiro[5.5]undecane-9-carboxylate;4-oxo-1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid 1,1-dimethylethyl ester;TERT-BUTYL 4-OXO-1-OXA-9-AZASPIRO[5.5]UNDECANE-9-CARBOXYLATE(WX102670)
• CAS NO: 1346229-51-3
• Molecular Formula: C₁₄H₂₃NO₄
• Molecular Weight: 269.33672
• Mol File: 1346229-51-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-oxo-1-oxa-9-azaspiro[5.5]undecane-9-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-oxo-1-oxa-9-azaspiro[5.5]undecane-9-carboxylate(1346229-51-3)
• EPA Substance Registry System: tert-butyl 4-oxo-1-oxa-9-azaspiro[5.5]undecane-9-carboxylate(1346229-51-3)

Safety Data

• Hazardous Substances Data: 1346229-51-3(Hazardous Substances Data)

Upstream product

• 1785761-76-3 9-benzyl-1-oxa-9-azaspiro[5.5]undecan-4-ol 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 1354931-70-6 4-methylene-9-(t.butoxycarbonyl)-1-oxa-9-azaspiro[5.5]undecane 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1346229-50-2 tert-butyl 8-oxo-11-oxa-3-azaspiro[5.5]undec-9-ene-3-carboxylate 
• 374796-29-9 tert-butyl 4-hydroxy-1-oxa-9-azaspiro[5.5]undecane-9-carboxylate 
• 374795-40-1 tert-butyl 1-oxa-9-azaspiro[5.5]undec-3-ene-9-carboxylate 
• 374795-39-8 tert-butyl 4-allyl-4-(allyloxy)piperidine-1-carboxylate 
• 203662-51-5 1-(t-butoxycarbonyl)-4-(prop-2-enyl)-4-hydroxypiperidine 

Relevant articles and documents

Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835

The free fatty acid receptor 1 (FFA1), a G protein-coupled receptor (GPCR) naturally activated by long-chain fatty acids is a novel target for the treatment of metabolic diseases. The basic amine spirocyclic periphery of Eli Lilly's drug candidate LY2881835 for treatment of type 2 diabetes mellitus (which reached phase I clinical trials) inspired a series of novel FFA1 agonists. These were designed to incorporate the 3-[4-(benzyloxy)phenyl]propanoic acid pharmacophore core decorated with a range of spirocyclic motifs. The latter were prepared via the Prins cyclization and subsequent modification of the 4-hydroxytetrahydropyran moiety in the Prins product. Here, we synthesize 19 compounds and test for FFA1 activity. Within this pilot set, a nanomolar potency (EC50?=?55?nM) was reached. Four lead compounds (EC50range 55–410?nM) were characterized for aqueous solubility, metabolic stability, plasma protein binding and Caco-2 permeability. While some instability in the presence of mouse liver microsomes was noted, mouse pharmacokinetic profile of the compound having the best overall ADME properties was evaluated to reveal acceptable bioavailability (F?=?10.3%) and plasma levels achieved on oral administration.

CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.